Processing

Please wait...

Settings

Settings

Goto Application

1. WO2019051125 - AMINOBENZIMIDAZOLE DERIVATIVES, TREATMENTS, AND METHODS OF INHIBITING HISTONE DEACETYLASE

Publication Number WO/2019/051125
Publication Date 14.03.2019
International Application No. PCT/US2018/049801
International Filing Date 06.09.2018
IPC
C07D 235/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
235Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
02condensed with carbocyclic rings or ring systems
04Benzimidazoles; Hydrogenated benzimidazoles
24with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
30Nitrogen atoms not forming part of a nitro radical
C07D 401/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
C07D 403/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
CPC
A61K 31/4184
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4184condensed with carbocyclic rings, e.g. benzimidazoles
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 235/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
235Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
02condensed with carbocyclic rings or ring systems
04Benzimidazoles; Hydrogenated benzimidazoles
24with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
30Nitrogen atoms not forming part of a nitro radical
C07D 405/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
06linked by a carbon chain containing only aliphatic carbon atoms
Applicants
  • TRANSLATIONAL DRUG DEVELOPMENT, LLC [US]/[US]
Inventors
  • WANG, Tong
  • GATELY, Stephen
Agents
  • FULLER, Rodney J.
Priority Data
62/554,72806.09.2017US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) AMINOBENZIMIDAZOLE DERIVATIVES, TREATMENTS, AND METHODS OF INHIBITING HISTONE DEACETYLASE
(FR) DÉRIVÉS D'AMINOBENZIMIDAZOLE, TRAITEMENTS ET MÉTHODES D'INHIBITION DE L'HISTONE DÉSACÉTYLASE
Abstract
(EN)
The present invention is directed to novel aminobenzimidazole derivatives. The present invention is also directed to methods of treating a histone deacetylase (HDAC)-associated disease or inhibiting the histone deacetylating activity of a HDAC isoform in a cell or with one or more of the aminobenzimidazole derivatives.
(FR)
La présente invention concerne de nouveaux dérivés d'aminobenzimidazole. La présente invention concerne également des méthodes de traitement d'une maladie associée à l'histone désacétylase (HDAC) ou d’inhibition de l'activité de désacétylation de l'histone d'un isoforme de la HDAC dans une cellule ou avec un ou plusieurs des dérivés d'aminobenzimidazole.
Also published as
JP2020513848
Latest bibliographic data on file with the International Bureau